142 related articles for article (PubMed ID: 2106723)
1. Tumour necrosis factor in hepatosplenic schistosomiasis.
Zwingenberger K; Irschick E; Vergetti Siqueira JG; Correia Dacal AR; Feldmeier H
Scand J Immunol; 1990 Feb; 31(2):205-11. PubMed ID: 2106723
[TBL] [Abstract][Full Text] [Related]
2. Praziquantel in the treatment of hepatosplenic schistosomiasis: biochemical disease markers indicate deceleration of fibrogenesis and diminution of portal flow obstruction.
Zwingenberger K; Richter J; Vergetti JG; Feldmeier H
Trans R Soc Trop Med Hyg; 1990; 84(2):252-6. PubMed ID: 2117787
[TBL] [Abstract][Full Text] [Related]
3. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni.
Mwatha JK; Kimani G; Kamau T; Mbugua GG; Ouma JH; Mumo J; Fulford AJ; Jones FM; Butterworth AE; Roberts MB; Dunne DW
J Immunol; 1998 Feb; 160(4):1992-9. PubMed ID: 9469463
[TBL] [Abstract][Full Text] [Related]
4. T cell phenotype alterations in hepatosplenic schistosomiasis mansoni normalize after chemotherapy.
Zwingenberger K; Harms G; Vergetti de Siqueira JG; Correia Dacal AR; Jansen-Rosseck R; Bienzle U; Feldmeier H
Immunobiology; 1989 Oct; 179(4-5):342-52. PubMed ID: 2515152
[TBL] [Abstract][Full Text] [Related]
5. Altered generation of interleukin 1 in chronic human schistosomiasis mansoni.
Zwingenberger K; Richter J; Taupitz S; Vergetti Siqueira JG; Correia Dacal AR
Scand J Immunol; 1990 Jun; 31(6):729-36. PubMed ID: 2113308
[TBL] [Abstract][Full Text] [Related]
6. Reduction of morbidity in hepatosplenic schistosomiasis mansoni after treatment with praziquantel: a long term study.
Domingues AL; Coutinho AD
Rev Soc Bras Med Trop; 1990; 23(2):101-7. PubMed ID: 2129517
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatosplenic Schistosomiasis mansoni with praziquantel. Preliminary report on tolerance and efficacy.
Coutinho A; Domingues AL; Neves J; Almeida ST
Arzneimittelforschung; 1983; 33(5):787-91. PubMed ID: 6683560
[No Abstract] [Full Text] [Related]
8. Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease.
Colley DG; Garcia AA; Lambertucci JR; Parra JC; Katz N; Rocha RS; Gazzinelli G
Am J Trop Med Hyg; 1986 Jul; 35(4):793-802. PubMed ID: 3089040
[TBL] [Abstract][Full Text] [Related]
9. Liver involvement in human schistosomiasis mansoni. Regression of immunological and biochemical disease markers after specific treatment.
Zwingenberger K; Harms G; Feldmeier H; Müller O; Steiner A; Bienzle U
Acta Trop; 1988 Sep; 45(3):263-75. PubMed ID: 2903628
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cytokines IL-10 and IL-13 as mediators in the progression of Symmers fibrosis in patients with hepatosplenic schistosomiasis mansoni.
Brandt CT; Rino M; Pitta MG; Muniz JS; Silveira Dde O; Castro CM
Rev Col Bras Cir; 2010 Oct; 37(5):333-7. PubMed ID: 21180998
[TBL] [Abstract][Full Text] [Related]
11. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers.
Zwingenberger K; Feldmeier H; Queiroz JA; Siqueira JG; Auto HF; Alencar JE; Bienzle U
Parasitol Res; 1988; 74(5):448-55. PubMed ID: 3137558
[TBL] [Abstract][Full Text] [Related]
12. Specific treatment of hepatosplenic schistosomiasis can increase T-lymphocyte reactivity.
Muniz-Junqueira MI; Tavares-Neto J; Ataide M; Prata A; Tosta CE
Rev Soc Bras Med Trop; 1991; 24(2):97-9. PubMed ID: 1841433
[TBL] [Abstract][Full Text] [Related]
13. Immunology of hepatosplenic schistosomiasis mansoni: a human perspective.
Dunne DW; Pearce EJ
Microbes Infect; 1999 Jun; 1(7):553-60. PubMed ID: 10603572
[No Abstract] [Full Text] [Related]
14. T cell-dependent immunodepression in vivo in Schistosoma mansoni infected patients.
Muniz-Junqueira MI; Tosta CE; Prata A
Rev Soc Bras Med Trop; 1990; 23(1):27-31. PubMed ID: 2128545
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of hepatosplenic schistosomiasis mansoni with praziquantel].
Coutinho AD; Domingues AL; Florêncio JN; Almeida ST
Rev Inst Med Trop Sao Paulo; 1984; 26(1):38-50. PubMed ID: 6379831
[No Abstract] [Full Text] [Related]
16. Is the coagulopathy of hepatosplenic schistosomiasis immune-related?
Amer AM; el Defrawi IE; el Sherif NH; el Khayat HR
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):789-93. PubMed ID: 7865686
[TBL] [Abstract][Full Text] [Related]
17. Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni.
da Silva LC; Sette H; Christo CH; Sáez-Alquezar A; Carneiro CR; Lacet CM; Ohtsuki N; Raia S
Arzneimittelforschung; 1981; 31(3a):601-3. PubMed ID: 7195256
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses in human hepatosplenic schistosomiasis mansoni.
Goodgame RW; Colley DG; Draper CC; Lewis FA; McLaren ML; Pelley RP
Am J Trop Med Hyg; 1978 Nov; 27(6):1174-80. PubMed ID: 727322
[TBL] [Abstract][Full Text] [Related]
19. Immune profiles in hepatosplenic schistosomiasis mansoni after surgical treatments.
Petroianu A; Antunes LJ
J Int Med Res; 1998; 26(1):43-9. PubMed ID: 9513076
[TBL] [Abstract][Full Text] [Related]
20. [Clinical immunology of hepato-splenic bilharziasis].
Esterre P; Boisier P; Ravaolimalala VA; Roux J
Arch Inst Pasteur Madagascar; 1994; 61(1):28-30. PubMed ID: 7778947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
